"Quinazolines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D011799
|
| MeSH Number(s) |
D03.633.100.786
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Quinazolines".
Below are MeSH descriptors whose meaning is more specific than "Quinazolines".
This graph shows the total number of publications written about "Quinazolines" by people in this website by year, and whether "Quinazolines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 1 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 1 | 2 |
| 2001 | 2 | 1 | 3 |
| 2002 | 3 | 5 | 8 |
| 2003 | 6 | 1 | 7 |
| 2004 | 10 | 7 | 17 |
| 2005 | 7 | 6 | 13 |
| 2006 | 9 | 11 | 20 |
| 2007 | 24 | 13 | 37 |
| 2008 | 15 | 18 | 33 |
| 2009 | 14 | 10 | 24 |
| 2010 | 22 | 8 | 30 |
| 2011 | 25 | 18 | 43 |
| 2012 | 12 | 18 | 30 |
| 2013 | 14 | 27 | 41 |
| 2014 | 13 | 14 | 27 |
| 2015 | 13 | 19 | 32 |
| 2016 | 5 | 8 | 13 |
| 2017 | 8 | 7 | 15 |
| 2018 | 2 | 6 | 8 |
| 2019 | 8 | 1 | 9 |
| 2020 | 1 | 4 | 5 |
| 2021 | 8 | 6 | 14 |
| 2022 | 1 | 6 | 7 |
| 2023 | 0 | 4 | 4 |
| 2024 | 2 | 3 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Quinazolines" by people in Profiles.
-
A Phase I Open-Label Study of Cediranib Plus Etoposide and Cisplatin as First-Line Therapy for Patients With Extensive-Stage Small-Cell Lung Cancer or Metastatic Neuroendocrine Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2024 Nov; 25(7):601-611.
-
Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer. ESMO Open. 2024 Jun; 9(6):103465.
-
CLO24-088: Efficacy of Fruquintinib in Less Heavily Pretreated Patients (Pts) With Metastatic Colorectal Cancer (mCRC): Profile-Matched Data From FRESCO and FRESCO-2. J Natl Compr Canc Netw. 2024 Apr 05; 22(2.5).
-
Mortality in recipients of allogeneic haematopoietic cell transplantation in the era of cytomegalovirus primary prophylaxis: a single-centre retrospective experience. Clin Microbiol Infect. 2024 Jun; 30(6):803-809.
-
Current and Emerging Antiviral Agents in the Prevention and Treatment of Cytomegalovirus in Pediatric Transplant Recipients. J Pediatric Infect Dis Soc. 2024 Feb 28; 13(Supplement_1):S14-S21.
-
Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study. ESMO Open. 2023 Dec; 8(6):101609.
-
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer. N Engl J Med. 2023 Nov 16; 389(20):1851-1861.
-
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer. Clin Cancer Res. 2023 08 15; 29(16):3101-3109.
-
Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma. Clin Cancer Res. 2023 04 03; 29(7):1200-1208.
-
Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium in vivo models of osteosarcoma. Pediatr Blood Cancer. 2023 01; 70(1):e30017.